. 2019 Jul 24;20(1):84. doi: 10.1186/s10194-019-1032-x

Table 3.

Odds ratios for lasmiditan treatment versus placebo were similar or greater in the group of patients using preventives than in those not using preventives

Outcome	Lasmiditan dose (mg)	Using preventives		Not using preventives		Interaction p-value^b
Outcome	Lasmiditan dose (mg)	n/N (%)	Odds ratio^a (CI)	n/N (%)	Odds ratio^a (CI)	Interaction p-value^b
Pain-free at 2 h	PBO	23/196 (11.7)		172/867 (19.8)
	50	25/104 (24.0)	2.2 (1.0, 4.7)	134/452 (29.6)	1.4 (1.0, 1.9)	0.715
	100	44/175 (25.1)	2.5 (1.4, 4.4)	265/860 (30.8)	1.8 (1.4, 2.2)	0.654
	200	51/167 (30.5)	3.3 (1.9, 5.7)	321/879 (36.5)	2.3 (1.9, 2.9)	0.550
MBS-free at 2 h	PBO	45/189 (23.8)		271/813 (33.3)
	50	37/97 (38.1)	2.0 (1.1, 3.7)	172/415 (41.4)	1.3 (1.0, 1.7)	0.342
	100	55/160 (34.4)	1.7 (1.0, 2.7)	358/809 (44.3)	1.6 (1.3, 1.9)	0.523
	200	60/152 (39.5)	2.1 (1.3, 3.3)	371/812 (45.7)	1.7 (1.4, 2.1)	0.674

CI confidence interval, MBS most bothersome symptom, N number of patients in the subgroup of mITT population, n number of patients achieving outcome, PBO placebo

^aOdds ratio compared to patients who received placebo in the same subgroup

^bInteraction p-value comparing patients using and patients not using migraine preventive medications